Santhera Pharmaceuticals (SWX:SANN) was informed by Deka Investment GmbH, Mainzer Landstrasse 16, 60325 Frankfurt am Main, Germany, that the following funds under its management
- Deka Pharma Tech
- Deka Bio-Tech
- Deka Schweiz
- Deka Institutionell Aktien Europa
have reduced their shareholdings of Santhera Pharmaceuticals Holding Ltd to below 5% of the shares registered in the Commercial Register.
* * *
For Further Information, Contact
Thomas Staffelbach, VP Public & Investor Relations
phone: +41 (0)61 906 89 47
Disclaimer/Forward-looking Statements
This news release is not and under no circumstances is to be construed as a solicitation, offer, or recommendation, to buy or sell securities issued by Santhera. Santhera makes no representation (either express or implied) that the information and opinions expressed in this news release are accurate, complete or up to date. Santhera disclaims, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information contained in this news release.
Forward-looking statements and other information contained in this release involve risks and uncertainties. Such statements reflect the current views, intentions and estimates of the Company. They are based on assumptions that may be inaccurate. Results could differ materially from those anticipated. Certain of these forward-looking statements can be identified by the use of forward-looking terminology such as "believe", "expect", "may", "are expected to", "will", "will continue", "should", "would be", "seek" or "anticipate" or by discussions of strategy, plans or intentions. Furthermore, the Company does not assume any obligation to update these forward-looking statements.
